{"Content: ":"BriLife, also known as IIBR-100, is a replication-competent recombinant VSV viral vectored COVID-19 vaccine candidate.[1][2][3][4] It was developed by the Israel Institute for Biological Research (IIBR).[1][5][6] The IIBR partnered with the US-based NRx Pharmaceuticals to complete clinical trials and commercialize the vaccine.[7][8] A study conducted in hamsters suggested that one dose of the vaccine was safe and effective at protecting against COVID-19.[9][3] This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it.","Title":"BriLife - Wikipedia","KeyID":"11184","URL":"https://en.wikipedia.org/wiki/BriLife"}